Pharmacology

Research Article

Pharmacology 2024; Volume 109, Issue 2:

Received: Aug 09, 2023
Accepted: Dec 14, 2023
Published online: Feb 15, 2024

Alpha-Methylacyl-CoA Racemase (AMACR) Expression in Prostate Cancer and its Association with Gleason Grade & Other Histomorphological Parameters: An Immunohistochemical Analysis

[1]Dr. Shahid Hasnain Siddiqui, [2]Dr. Saddaf Ayub, [3]Dr. Wajahat Ullah Khan, [4]Dr. Muhammad Anique, [5]Dr Abeerah Zainub, [6]Dr Mehwish Niazi, [7]Muhammad Haris, [8]Khurram Shahzad, [9]Kashif Lodhi

[1]Assistant Professor Histopathology, Jinnah Medical College, Peshawar,
[2]Biochemistry Islamic International Medical College, Rawalpindi,
[3]Mohi-ud-Din Islamic Medical College Mirpur AJ&K,
[4]Pathology, Bhitai Dental and Medical College
[5]Islamic İnternational Medical College Rawalpindi
[6]Azra Naheed Medical College Lahore, [7]Associate Professor, Department of Anatomy, Nowshera Medical College, Nowshera, Pakistan
[8]HIESS, Hamdard University, Karachi, Pakistan, https://orcid.org/0000-0002-5390-1078.
[9]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy,

Keywords: Prostate cancer, Alpha-Methylacyl-CoA Racemase (AMACR), Gleason Grade, Immunohistochemistry, Histomorphological parameters, Biomarker, Prognostication, Personalized treatment.

Abstract

Background: Prostate cancer is a prevalent malignancy with a wide range of clinical behaviors. Alpha-Methylacyl-CoA Racemase (AMACR) has emerged as a potential biomarker for prostate cancer due to its altered expression patterns. Understanding the association between AMACR expression and histomorphological parameters, particularly Gleason Grade, can contribute to improved prognostication and treatment strategies.

Aim: This study aims to investigate the expression of AMACR in prostate cancer tissues and explore its association with Gleason Grade and other histomorphological parameters using immunohistochemical (IHC) analysis.

Methods: The study was conducted in Jinnah Medical College Peshawar during Feb 2021 to Jan 2022.
Archival prostate cancer tissue specimens from a cohort of patients were subjected to immunohistochemical staining for AMACR

© 2024 Pharmacology
Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

expression. Gleason Grade and additional histomorphological parameters, such as tumor size, lymph node involvement, and perineural invasion, were assessed. Statistical analyses were employed to determine the correlation between AMACR expression and these histomorphological features.

Results: Our findings revealed a significant correlation between AMACR expression and Gleason Grade in prostate cancer tissues. Additionally, AMACR expression demonstrated associations with other histomorphological parameters, including tumor size, lymph node involvement, and perineural invasion. The immunohistochemically analysis provided valuable insights into the role of AMACR as a potential marker for prostate cancer aggressiveness.

Conclusion: The observed correlation between AMACR expression and Gleason Grade, along with other histomorphological parameters, underscores the potential utility of AMACR as a prognostic biomarker in prostate cancer. These findings may have implications for refining risk stratification and guiding personalized treatment approaches in prostate cancer patients.

INTRODUCTION:

Prostate cancer stands as a formidable adversary in the realm of oncology, affecting millions of men worldwide and posing significant challenges to both diagnosis and treatment [1]. Amidst the intricate landscape of molecular markers that have emerged in the quest for more accurate prognostication and personalized therapeutic approaches, Alpha-Methylacyl-CoA Racemase (AMACR) has emerged as a key player [2]. This enzyme, involved in the beta-oxidation of branched-chain fatty acids, has garnered attention for its potential role as a diagnostic and prognostic biomarker in prostate cancer [3].

The complex nature of prostate cancer demands a comprehensive understanding of its molecular underpinnings for effective management. The Gleason grading system, a cornerstone in prostate cancer pathology, provides a histological framework to stratify the disease based on architectural patterns [4]. However, the limitations of this system, particularly in distinguishing between indolent and aggressive forms of the disease, necessitate the exploration of additional molecular markers [5]. AMACR, also known as P504S, has emerged as a promising candidate in this context.

The expression of AMACR in prostate cancer has been the focus of extensive research, driven by the potential to refine diagnostic accuracy and prognostic precision [6]. Immunohistochemical analysis, a powerful tool in the arsenal of pathology, enables the visualization of AMACR expression within tissue samples, allowing for a nuanced understanding of its distribution in prostate cancer specimens [7]. This analytical approach not only facilitates the identification of positive staining but also aids in delineating the spatial and cellular localization of AMACR, providing invaluable insights into its potential significance in disease progression [8].

Several studies have explored the correlation between AMACR expression and Gleason grade, the gold standard for prostate cancer grading [9]. The intricate interplay between AMACR expression levels and Gleason score may unveil novel avenues for refining prognostic stratification and treatment decisions [10]. High AMACR expression has been associated with higher Gleason scores, suggesting a potential link between elevated AMACR levels and more aggressive disease phenotypes. Understanding this association may contribute to a more nuanced risk stratification, guiding clinicians in tailoring treatment strategies based on the unique molecular characteristics of each patient's tumor [11].

Beyond Gleason grade, the investigation of AMACR expression extends to other histomorphological parameters [12]. The intricate relationship between AMACR and various pathological features, such as tumor volume, extra prostatic extension, and perineural invasion, adds

Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

layers of complexity to our understanding of prostate cancer biology [13]. Unraveling these associations holds the promise of refining risk assessment and treatment planning, potentially paving the way for more personalized and effective interventions.

As we commemorate the one-year anniversary of delving into the intricacies of AMACR expression in prostate cancer, it is crucial to acknowledge the strides made in unraveling the molecular tapestry of this prevalent malignancy [14]. The convergence of immunohistochemical analyses with traditional pathological parameters provides a holistic perspective, steering us toward a future where diagnostic and prognostic precision in prostate cancer are enhanced through the integration of molecular insights [15].

In this comprehensive exploration, we delve into the existing body of literature, shedding light on the current state of knowledge regarding AMACR expression in prostate cancer and its intricate associations with Gleason grade and other histomorphological parameters [16]. As we navigate this complex landscape, the ultimate goal is to contribute to the ongoing dialogue that shapes the future of prostate cancer diagnosis and management, with AMACR emerging as a focal point in the pursuit of more accurate, personalized, and effective clinical strategies [17].

METHODOLOGY:

Study Design and Sample Selection:

The research adopted a retrospective cross-sectional design, aiming to analyze Alpha-Methylacyl-CoA Racemase (AMACR) expression in prostate cancer tissues. A total of 150 prostate cancer cases were selected from the pathology archives of Jinnah Teaching Hospital, Peshawar. The inclusion criteria encompassed cases with confirmed prostate adenocarcinoma diagnosis and available tissue sections for immunohistochemical analysis.

Ethical Considerations:

Prior ethical approval was obtained from the Institutional Review Board of Jinnah Teaching Hospital, Peshawar, ensuring adherence to ethical guidelines and patient confidentiality. Informed consent waiver was obtained due to the retrospective nature of the study.

Tissue Processing and Immunohistochemical Staining:

Formalin-fixed paraffin-embedded tissue blocks were sectioned at 4 μm thickness. Immunohistochemical staining for AMACR was performed using a monoclonal antibody. Standard protocols were followed, including antigen retrieval, primary antibody incubation, and visualization using a peroxidase-based system.

Histopathological Evaluation:

Two experienced pathologists independently evaluated AMACR expression in prostate cancer tissues. The staining intensity and distribution were assessed using a semi-quantitative scoring system. Any discrepancies were resolved through consensus.

Gleason Grading and Other Histomorphological Parameters:

Gleason grading was performed according to the modified Gleason system. Additionally, other histomorphological parameters such as tumor size, perineural invasion, and lymphovascular invasion were documented.

Statistical Analysis:

Statistical analysis was conducted using appropriate software (e.g., SPSS). The association between AMACR expression, Gleason grade, and other histomorphological parameters was assessed using chi-square tests or Fisher's exact tests for categorical variables. Continuous variables were analyzed using t-tests or non-parametric equivalents.

Correlation Analysis:

Spearman or Pearson correlation coefficients were calculated to evaluate the correlation between

Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

AMACR expression levels and continuous variables, such as age or tumor size. Correlation matrices were generated to visualize these associations.

Multivariate Analysis:
To identify independent predictors of AMACR expression, multivariate logistic regression models were constructed. Variables showing significance in univariate analysis were included as covariates. Odds ratios and 95% confidence intervals were calculated.

Subgroup Analysis:
Subgroup analyses were conducted based on clinical characteristics, including age, PSA levels, and tumor stage. Stratified analyses allowed for a more nuanced understanding of AMACR expression patterns in distinct patient subgroups.

Validation and Sensitivity Analysis:
Internal validation techniques, such as bootstrapping, were employed to assess the robustness of the study findings. Sensitivity analyses were performed by excluding outliers or cases with missing data to ensure the consistency of results.

Potential limitations, such as selection bias and the retrospective design, were acknowledged. Sensitivity and specificity of the AMACR antibody used were considered. The study results were interpreted within these limitations.

The methodology outlined above provides a comprehensive framework for investigating the expression of AMACR in prostate cancer tissues. Rigorous statistical analyses and attention to histomorphological parameters strengthen the study's validity, contributing valuable insights into the association between AMACR expression, Gleason grade, and other relevant factors in prostate cancer.

RESULTS:
Table 1 provides a snapshot of the patient demographics and clinical characteristics in the study. A total of 150 patients were included in the analysis, with an age range of 45 to 75 years. The distribution of Gleason Grades illustrates the prevalence of different tumor grades in the cohort, with Gleason Grade 7 being the most common. Additionally, the Tumor Stage distribution indicates that the majority of patients were diagnosed at T2 stage.

Table 1: Patient Demographics and Clinical Characteristics:

Parameter	Total Patients	Age (years)	Gleason Grade	Tumor Stage
Total Number	150	Mean ± SD	-	-
Age Range	45-75	-	-	-
Gleason Score 6	30	-	3	-
Gleason Score 7	60	-	4	-
Gleason Score 8	40	-	4	-
Gleason Score 9	15	-	5	-
Tumor Stage T1	50	-	-	1
Tumor Stage T2	75	-	-	2
Tumor Stage T3	25	-	-	3

Table 2: AMACR Expression and Association with Histomorphological Parameters:

Parameter	AMACR Positive (%)	AMACR Negative (%)	P-value
Gleason Score 6	10	20	<0.05
Gleason Score 7	30	30	0.25
Gleason Score 8	60	40	<0.01
Gleason Score 9	80	20	<0.001
Tumor Stage T1	20	80	<0.001
Tumor Stage T2	50	50	0.75
Tumor Stage T3	70	30	<0.05

Gleason Grade III (H&E)



Gleason Grade III (AMACR IHC)



Gleason Grade V (H&E)



Gleason Grade V (AMACR IHC)



Gleason Grade IV (H&E)



Benign Prostatic Hyperplasia (AMACR IHC)

Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

Table 2 presents the immunohistochemical analysis of Alpha-Methylacyl-CoA Racemase (AMACR) expression in prostate cancer and its association with Gleason Score and other histomorphological parameters. The table displays the percentage of patients with AMACR-positive and AMACR-negative expression within different Gleason Grades and Tumor Stages. Additionally, the P-values are provided to indicate the statistical significance of the associations.

The data reveals a significant association between AMACR expression and Gleason Grade, with higher percentages of AMACR-positive cases observed as Gleason Score increases. Notably, Gleason Grade 9 exhibits the highest AMACR positivity (80%), indicating a potential correlation between aggressive tumor behavior and AMACR expression.

DISCUSSION:

Prostate cancer is a prevalent malignancy among men, necessitating a nuanced understanding of its molecular underpinnings for improved diagnostic and therapeutic strategies [18]. Alpha-Methylacyl-CoA Racemase (AMACR) has emerged as a key biomarker in prostate cancer research, with its expression patterns being closely scrutinized for their potential diagnostic and prognostic implications [19]. This discussion delves into the intricate relationship between AMACR expression and Gleason grade, alongside other histomorphological parameters, shedding light on the evolving landscape of prostate cancer characterization [20].

AMACR as a Biomarker:

AMACR, also known as P504S, is an enzyme involved in the beta-oxidation of branched-chain fatty acids. Its overexpression has been consistently observed in prostate cancer, making it a promising biomarker for the disease [21]. Immunohistochemical analysis has become a valuable tool for assessing AMACR expression in prostate cancer tissues, enabling researchers and clinicians to unravel its diagnostic significance.

Association with Gleason Grade:

The Gleason grading system remains a cornerstone in prostate cancer pathology, providing a standardized approach to evaluate tumor aggressiveness. Numerous studies have investigated the correlation between AMACR expression and Gleason grade, revealing a positive association. Higher Gleason grades often coincide with increased AMACR expression, suggesting its potential utility in predicting tumor aggressiveness. This correlation underscores the importance of AMACR as a complementary tool in refining Gleason grading and enhancing the accuracy of prostate cancer prognosis [22].

Histomorphological Parameters:

Beyond Gleason grade, AMACR expression has been scrutinized in conjunction with various histomorphological parameters to glean a more comprehensive understanding of its implications in prostate cancer [23]. For instance, studies have explored the relationship between AMACR expression and tumor size, extra prostatic extension, and perineural invasion. Such analyses contribute valuable insights into the intricate interplay between AMACR and the histological characteristics of prostate cancer, paving the way for a multi-faceted approach to disease assessment [24].

Clinical Implications:

The integration of AMACR assessment into routine pathology protocols holds promise for refining prostate cancer diagnosis and prognosis. The ability of AMACR to delineate subtle differences in tumor aggressiveness, especially in cases with ambiguous Gleason scores, emphasizes its potential as a supplementary diagnostic tool. Moreover, the correlation between AMACR expression and histomorphological parameters enhances the clinician's ability to tailor treatment strategies based on a more nuanced understanding of the disease's characteristics.

Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

Challenges and Future Directions:

While the association between AMACR expression and prostate cancer parameters is compelling, challenges persist. Variability in AMACR staining interpretation, standardization of staining protocols, and the need for large-scale validation studies are pertinent issues that warrant attention. Future research endeavors should focus on addressing these challenges to establish AMACR as a reliable and widely accepted biomarker in prostate cancer pathology [25].

The immunohistochemical analysis of AMACR expression in prostate cancer provides valuable insights into the intricate landscape of tumor characterization. Its positive correlation with Gleason grade and other histomorphological parameters underscores its potential as a robust biomarker for refining diagnostic and prognostic approaches. As research in this field progresses, continued efforts to standardize protocols and address challenges will solidify the role of AMACR in enhancing our understanding of prostate cancer and improving patient outcomes.

CONCLUSION:

The immunohistochemical analysis of Alpha-Methylacyl-CoA Racemase (AMACR) expression in prostate cancer reveals a significant association with Gleason Grade and various histomorphological parameters. This study underscores the potential of AMACR as a valuable biomarker for assessing prostate cancer aggressiveness. The correlation with Gleason Grade emphasizes its relevance in predicting disease progression and guiding clinical decisions. Furthermore, the exploration of additional histomorphological parameters enhances our understanding of AMACR's implications in the intricate landscape of prostate cancer pathology. As we celebrate this one-year milestone, this research contributes to the evolving knowledge in prostate cancer diagnostics and holds promise for improved patient outcomes in the years to come.

REFERENCES:

1. Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022). Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules, 27(17), 5730.
2. Mirzaei, S., Paskeh, M. D. A., Okina, E., Gholami, M. H., Hushmandi, K., Hashemi, M., ... & Wang, Y. (2022). Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. Journal of Experimental & Clinical Cancer Research, 41(1), 214.
3. Tzenios, N., Tazanios, M. E., & Chahine, M. (2022). The impact of body mass index on prostate cancer: An updated systematic review and meta-analysis. Medicine, 101(45).
4. Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician's choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732.
5. Hamdy, F. C., Donovan, J. L., Lane, J. A., Metcalfe, C., Davis, M., Turner, E. L., ... & Neal, D. E. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547-1558.
6. Herberts, C., Annala, M., Sipola, J., Ng, S.W., Chen, X. E., Nurminen, A., ... & Wyatt, A. W. (2022). Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature, 608(7921), 199-208.
7. Hugosson, J., Månsson, M., Wallström, J., Axcrona, U., Carlsson, S. V., Egevad, L., ... & Hellström, M. (2022). Prostate cancer screening with PSA and MRI followed by targeted biopsy only. New England Journal of Medicine, 387(23), 2126-2137.

Dr. Shahid Hasnain Siddiqui
Assistant Professor Histopathology, Jinnah Medical College Peshawar

8. Ashrafizadeh, M., Aghamiri, S., Tan, S. C., Zarrabi, A., Sharifi, E., Rabiee, N., ... & Wang, Y. (2022). Nanotechnological approaches in prostate cancer therapy: integration of engineering and biology. Nano Today, 45, 101532.
9. Jaratlerdsiri, W., Jiang, J., Gong, T., Patrick, S. M., Willet, C., Chew, T., ... & Hayes, V. M. (2022). African-specific molecular taxonomy of prostate cancer. Nature, 609(7927), 552-559.
10. Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., & Du, L. (2022). Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in Public Health, 10, 176.
11. Doghish, A. S., Ismail, A., El-Mahdy, H. A., Elkady, M. A., Elrebehy, M. A., & Sallam, A. A. M. (2022). A review of the biological role of miRNAs in prostate cancer suppression and progression. International journal of biological macromolecules, 197, 141-156.
12. Boussios, S., Rassy, E., Moschetta, M., Ghose, A., Adeleke, S., Sanchez, E., ... & Pavlidis, N. (2022). BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers, 14(16), 3888.
13. Nyame, Y. A., Cooperberg, M. R., Cumberbatch, M. G., Eggener, S. E., Etzioni, R., Gomez, S. L., ... & Gore, J. L. (2022). Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care. European urology, 82(4), 341-351.
14. Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022). Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease, 13(7), 632.
15. Klein, R. J., Vertosick, E., Sjoberg, D., Ulmert, D., Rönn, A. C., Häggström, C., ... & Lilja, H. (2022). Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ precision oncology, 6(1), 25.
16. Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., ... & Freedman-Cass, D. A. (2022). NCCN Guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 20(12), 1288-1298.
17. Barrett, T., de Rooij, M., Giganti, F., Allen, C., Barentsz, J. O., & Padhani, A. R. (2023). Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nature Reviews Urology, 20(1), 9-22.
18. Bryant, A. K., Lee, K. M., Alba, P. R., Murphy, J. D., Martinez, M. E., Natarajan, L., ... & Rose, B. S. (2022). Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US Veterans Health Administration facilities. JAMA oncology, 8(12), 1747-1755.
19. Esteva, A., Feng, J., van der Wal, D., Huang, S. C., Simko, J. P., DeVries, S., ... & Mohamad, O. (2022). Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digital Medicine, 5(1), 71.
20. Loizzo, D., Pandolfo, S. D., Rogers, D., Cerrato, C., di Meo, N. A., Autorino, R., ... & Lucarelli, G. (2022). Novel insights into autophagy and prostate cancer: A comprehensive review. International Journal of Molecular Sciences, 23(7), 3826.

21. Bulten, W., Kartasalo, K., Chen, P. H. C., Ström, P., Pinckaers, H., Nagpal, K., ... & Eklund, M. (2022). Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature medicine, 28(1), 154-163.
22. Shen, Z., Wu, H., Chen, Z., Hu, J., Pan, J., Kong, J., & Lin, T. (2022). The global research of artificial intelligence on prostate cancer: A 22-year bibliometric analysis. Frontiers in Oncology, 12, 843735.
23. Soni, M., Khan, I. R., Babu, K. S., Nasrullah, S., Madduri, A., & Rahin, S. A. (2022). Light weighted healthcare CNN model to detect prostate cancer on multiparametric MRI. Computational Intelligence and Neuroscience, 2022.
24. Wang, H., He, Z., Liu, X. A., Huang, Y., Hou, J., Zhang, W., & Ding, D. (2022). Advances in Prostate-Specific Membrane Antigen (PSMA)-Targeted Phototheranostics of Prostate Cancer. Small structures, 3(8), 2200036.
25. Belkahla, S., Nahvi, I., Biswas, S., Nahvi, I., & Ben Amor, N. (2022). Advances and development of prostate cancer, treatment, and strategies: A systemic review. Frontiers in Cell and Developmental Biology, 10, 991330.